Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Twi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

Twi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

TAIPEI, Aug. 3, 2015 /PRNewswire/ -- TWi Biotechnology, Inc., today announced that it has received Notices of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from the European Patent Office and the Patent Office of the Russian Federation for patent applications numbered 11766702.2-1460 and 2012147449, respectively. [More]
Integrated treatment required for diabetes-eating disorder combination

Integrated treatment required for diabetes-eating disorder combination

As they reach their teens, many with type 1 diabetes discover that the disease provides a secret weapon for losing weight. By restricting or reducing the amount of insulin they inject, they can eat just about anything they want and control their weight. [More]
LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL. [More]
IOF, EOS to jointly hold Middle East & Africa Osteoporosis Meeting in Abu Dhabi

IOF, EOS to jointly hold Middle East & Africa Osteoporosis Meeting in Abu Dhabi

With a growing senior population and an increase in unhealthy lifestyles, the prevalence of osteoporosis and Type 2 Diabetes Mellitus is soaring in the Middle East and North African region. In response to the dramatic increase in these diseases within the region the International Osteoporosis Foundation, in cooperation with the Emirates Osteoporosis Society, will be holding the 3rd Middle East & Africa Osteoporosis Meeting from December 5-7, 2015 in Abu Dhabi. [More]
EUMODIC brings together scientists to study functions of 320 genes in mice

EUMODIC brings together scientists to study functions of 320 genes in mice

Since mice share 90 percent of our genes they play an important role in understanding human genetics. The European Mouse Disease Clinic brought together scientists from across Europe to investigate the functions of 320 genes in mice. Over half of these genes had no previously known role, and the remaining genes were poorly understood. [More]
Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a very aggressive form of pulmonary fibrosis and has a particularly poor prognosis. This fatal disease, for which so far no causal therapies exist, is characterized by a massive deposition of connective and scar tissue in the lung, which leads to a progressive loss of lung function and ultimately death. [More]
Regular exercise, healthy diet may help reduce knee pain for overweight adults with diabetes

Regular exercise, healthy diet may help reduce knee pain for overweight adults with diabetes

Knee pain in older adults, often caused by osteoarthritis, usually means more visits to the doctor and also can be a harbinger of disability. [More]
Six hot line sessions set to reveal latest research in cardiovascular disease at ESC Congress 2015

Six hot line sessions set to reveal latest research in cardiovascular disease at ESC Congress 2015

Six hot line sessions at ESC Congress 2015 are set to reveal the latest in cardiovascular disease research across a range of conditions and comorbidities. Hot topics include atrial fibrillation, pacing, acute myocardial infarction, heart failure, hypertension, diabetes mellitus, pharmacology and coronary artery disease. [More]
New drug patiromer could improve potassium levels of patients with diabetic kidney disease

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Among patients with diabetic kidney disease and hyperkalemia (elevated potassium levels in the blood), a potentially life-threatening condition, those who received the new drug patiromer, twice daily for four weeks, had significant decreases in potassium levels which lasted through one year, according to a study in the July 14 issue of JAMA. [More]
Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs. [More]
Scientists elucidate which mechanisms block natural killer cells and how this could be lifted

Scientists elucidate which mechanisms block natural killer cells and how this could be lifted

Natural killer cells of the immune system can fend off malignant lymphoma cells and thus are considered a promising therapeutic approach. However, in the direct vicinity of the tumor they lose their effect. [More]
Resverlogix and Hepalink close license agreement, sign definitive stock purchase agreement

Resverlogix and Hepalink close license agreement, sign definitive stock purchase agreement

Resverlogix Corp. announced today that it has closed a license agreement and formally entered into a definitive stock purchase agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd.. [More]
Modified, healthier meal plan for youth with type 1 diabetes more expensive

Modified, healthier meal plan for youth with type 1 diabetes more expensive

Patients with type 1 diabetes mellitus (T1DM) often need to modify their eating habits, but many youths with T1DM do not consume a healthful diet. To learn more about the challenges their parents may face in providing them with a more healthful diet, researchers set out to discover the availability of healthier food options and the price difference of the food items at stores frequented by families in northeastern Kansas and western Missouri. [More]
Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS). [More]
Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Both spouses and first-degree relatives of patients with celiac disease are at increased risk of nonceliac autoimmune disease, according to a study in the July issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. This risk represents a mixture of genetic, environmental and ascertainment bias mechanisms. [More]
Neighborhood physical and social environments may affect type 2 diabetes risk

Neighborhood physical and social environments may affect type 2 diabetes risk

Neighborhood resources to support greater physical activity and, to a lesser extent, healthy diets appear to be associated with a lower incidence of type 2 diabetes, although the results vary by the method of measurement used, according to an article published online by JAMA Internal Medicine. [More]
ACT intervention may be effective in reducing risk for cardiovascular disease

ACT intervention may be effective in reducing risk for cardiovascular disease

A controlled study published in the current issue of Psychotherapy and Psychosomatic indicates the usefulness of a brief behavioral intervention targeting psychological risk factors for vascular disease. [More]
Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the VITROS Chemistry Products HbA1c Reagent Kit to be used on the VITROS 5600 Integrated System, VITROS 4600 Chemistry System, and the VITROS 5,1 FS Chemistry System. The test can be used for the quantitative determination of percent glycated hemoglobin A1c (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human whole blood. [More]
Helmholtz Zentrum München scientists identify how Epstein-Barr virus conceals in human cells

Helmholtz Zentrum München scientists identify how Epstein-Barr virus conceals in human cells

Scientists at Helmholtz Zentrum München have now discovered how Epstein-Barr virus (EBV) conceals itself in human cells. A main culprit for its bad visibility by the immune system is the viral protein LMP2A. As published in the scientific journal PLOS Pathogens, the protein helps EBV-infected cells hide from T cells. This camouflage through the LMP2A protein may play a major role in the causation of cancer by EBV. [More]
People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health as rates of nonfatal diseases and injuries - including diabetes and hearing loss - decline more slowly than death rates, according to a new analysis of 301 diseases and injuries in 188 countries. [More]
Advertisement
Advertisement